BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 34994029)

  • 1. Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study.
    Jiang H; Song B; Qin Y; Konanur M; Wu Y; McInnes MDF; Lafata KJ; Bashir MR
    J Magn Reson Imaging; 2022 Aug; 56(2):399-412. PubMed ID: 34994029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity.
    Jiang H; Song B; Qin Y; Wei Y; Konanur M; Wu Y; Zaki IH; McInnes MDF; Lafata KJ; Bashir MR
    J Magn Reson Imaging; 2022 Feb; 55(2):493-506. PubMed ID: 34236120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver imaging reporting and data system diagnostic performance in hepatocellular carcinoma when modifying the definition of "washout" on gadoxetic acid-enhanced magnetic resonance imaging.
    Hu W; Lyu R; Wang D; Gao Z; Sun C; Jia K
    Arab J Gastroenterol; 2024 Feb; 25(1):58-63. PubMed ID: 38245474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?
    Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J
    Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
    Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
    J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new classification and regression tree algorithm: Improved diagnostic sensitivity for HCC ≤ 3.0 cm using gadoxetate disodium-enhanced MRI.
    Pan J; Ye S; Song M; Yang T; Yang L; Zhu Y; Zhao Y; Chen F
    Eur J Radiol; 2023 May; 162():110770. PubMed ID: 36933495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.
    Chen J; Kuang S; Zhang Y; Tang W; Xie S; Zhang L; Rong D; He B; Deng Y; Xiao Y; Shi W; Fowler K; Wang J; Sirlin CB
    Abdom Radiol (NY); 2021 Apr; 46(4):1530-1542. PubMed ID: 33040166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging.
    Jang HJ; Choi SH; Choi SJ; Choi WM; Byun JH; Won HJ; Shin YM
    Eur Radiol; 2023 Aug; 33(8):5792-5800. PubMed ID: 37017700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended application of subtraction arterial phase imaging in LI-RADS version 2018: a strategy to improve the diagnostic performance for hepatocellular carcinoma on gadoxetate disodium-enhanced MRI.
    Kim SS; Lee S; Bae H; Chung YE; Choi JY; Park MS; Kim MJ
    Eur Radiol; 2021 Mar; 31(3):1620-1629. PubMed ID: 32886205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
    Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
    Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
    Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma.
    Kierans AS; Makkar J; Guniganti P; Cornman-Homonoff J; Lee MJ; Pittman M; Askin G; Hecht EM
    J Magn Reson Imaging; 2019 Jun; 49(7):e205-e215. PubMed ID: 30257054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Performance of 2018 LI-RADS versus Modified LIRADS (mLI-RADS): An Individual Participant Data Meta-Analysis.
    Goins SM; Jiang H; van der Pol CB; Salameh JP; Lam E; Adamo RG; McInnes MDF; Costa AF; Clarke C; Choi SH; Fraum TJ; Ludwig DR; Song B; Joo I; Kierans AS; Kim SY; Kwon H; Podgórska J; Rosiak G; Bashir MR
    J Magn Reson Imaging; 2023 Dec; ():. PubMed ID: 38038346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
    De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging.
    Yao S; Wei Y; Ye Z; Chen J; Duan T; Zhang Z; Song B
    J Magn Reson Imaging; 2024 Jun; 59(6):2060-2070. PubMed ID: 34121266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of gadoxetate disodium-enhanced MRI sequences for measuring hepatic observation size and its implication of LI-RADS classification.
    Choi JY; Ha J; Choi SH; Kang HJ; Kim SY; Kim KW
    Abdom Radiol (NY); 2022 Mar; 47(3):1024-1031. PubMed ID: 35020008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement.
    Vernuccio F; Cannella R; Meyer M; Choudhoury KR; Gonzáles F; Schwartz FR; Gupta RT; Bashir MR; Furlan A; Marin D
    AJR Am J Roentgenol; 2019 Aug; 213(2):W57-W65. PubMed ID: 31039012
    [No Abstract]   [Full Text] [Related]  

  • 20. LI-RADS v2018: utilizing ancillary features on gadoxetic acid-enhanced MRI to improve the diagnostic performance of small hapatocellular carcinoma (≤ 20 mm).
    Lyu R; Hu W; Wang D; Wang J; Gao Z; Jia K
    Abdom Radiol (NY); 2023 Jun; 48(6):1987-1994. PubMed ID: 36939913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.